303 related articles for article (PubMed ID: 21591886)
1. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility.
Matlock A; Allan N; Wills B; Kang C; Leikin JB
Clin Toxicol (Phila); 2011 Jul; 49(6):443-7. PubMed ID: 21591886
[TBL] [Abstract][Full Text] [Related]
2. FDA boxed warnings: how to prescribe drugs safely.
O'Connor NR
Am Fam Physician; 2010 Feb; 81(3):298-303. PubMed ID: 20112888
[TBL] [Abstract][Full Text] [Related]
3. Bringing greater transparency to "black box" warnings.
Buckley NA; Rossi S
Clin Toxicol (Phila); 2011 Jul; 49(6):448-51. PubMed ID: 21824055
[TBL] [Abstract][Full Text] [Related]
4. Droperidol, QT prolongation, and sudden death: what is the evidence?
Kao LW; Kirk MA; Evers SJ; Rosenfeld SH
Ann Emerg Med; 2003 Apr; 41(4):546-58. PubMed ID: 12658255
[TBL] [Abstract][Full Text] [Related]
5. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
Yeh JS; Sarpatwari A; Kesselheim AS
Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
[TBL] [Abstract][Full Text] [Related]
6. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
Murphy S; Roberts R
J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
[TBL] [Abstract][Full Text] [Related]
7. The Value of the Black Box Warning in Dermatology.
Winterfield L; Vleugels RA; Park KK
J Drugs Dermatol; 2015 Jul; 14(7):660-6. PubMed ID: 26151780
[TBL] [Abstract][Full Text] [Related]
8. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling.
Willy ME; Li Z
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):201-6. PubMed ID: 15255086
[TBL] [Abstract][Full Text] [Related]
9. The use of droperidol before and after the Food and Drug Administration black box warning: a survey of the members of the Society of Ambulatory Anesthesia.
Habib AS; Gan TJ
J Clin Anesth; 2008 Feb; 20(1):35-9. PubMed ID: 18346607
[TBL] [Abstract][Full Text] [Related]
10. FDA "black box" labeling.
Meyer RJ
Ann Emerg Med; 2003 Apr; 41(4):559-60. PubMed ID: 12658256
[No Abstract] [Full Text] [Related]
11. Prescribing Antipsychotic Medications to Patients With Dementia: Boxed Warnings and Mitigation of Legal Liability.
Rose RV; Kass JS
Continuum (Minneap Minn); 2019 Feb; 25(1):254-259. PubMed ID: 30707196
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of FDA Boxed Warning on Prescribing Patterns of Fluoroquinolones for Uncomplicated Urinary Tract Infections.
Cowart K; Worley M; Rouby NE; Sando K
Ann Pharmacother; 2019 Dec; 53(12):1192-1199. PubMed ID: 31319681
[No Abstract] [Full Text] [Related]
13. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
[TBL] [Abstract][Full Text] [Related]
15. Prospective Assessment of Inpatient Boxed Warning Prescriber Adherence.
Kloet MA; Lohr BR; Smithburger PL; Seybert AL; Kane-Gill SL
J Patient Saf; 2017 Mar; 13(1):25-30. PubMed ID: 24647270
[TBL] [Abstract][Full Text] [Related]
16. Boxed warning inconsistencies between drug information resources and the prescribing information.
Cheng CM; Fu C; Guglielmo BJ; Auerbach AD
Am J Health Syst Pharm; 2011 Sep; 68(17):1626-31. PubMed ID: 21856808
[TBL] [Abstract][Full Text] [Related]
17. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
[TBL] [Abstract][Full Text] [Related]
18. Impact of FDA Actions, DTCA, and Public Information on the Market for Pain Medication.
Bradford WD; Kleit AN
Health Econ; 2015 Jul; 24(7):859-75. PubMed ID: 25059655
[TBL] [Abstract][Full Text] [Related]
19. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
20. Surrogate markers, emboldened and boxed warnings, and an expanding culture of misinformation: evidence-based clinical science should guide FDA decision making about product labeling.
Shulman LP; Bateman LH; Creinin MD; Cullins VE; Doyle LL; Godfrey E; Murphy P; Rodriguez P; Spear SJ; Stewart FH; Thomas MA; Westhoff CL; Worthington S
Contraception; 2006 May; 73(5):440-2. PubMed ID: 16627028
[No Abstract] [Full Text] [Related]
[Next] [New Search]
